We Are Beating Multiple Myeloma Now. Join Us.

Multiple myeloma patients have options today because the status quo just a few years ago was, to us, unacceptable.

The model we have created for drug discovery and development is revolutionary. It brings multiple myeloma treatments to trial 60% faster than average. It has resulted in six multiple myeloma drugs receiving FDA approval in the time it normally takes for one. Through the power of new technology, genomics and immunology, it has extended lives that would have been lost to multiple myeloma yesterday. And it is accelerating all the time. Learn how we are doing it.

To improve the outcome, we partnered with
the best and rewrote the rules.

  • 2014
  • Plan to open 10 new trials
  • 2014
  • CoMMpass Study enrollment almost completed
  • 2014
  • MMRC launches
    50th clinical trial
  • 2013
  • CoMMunity and Researcher Gateways launched
  • 2013
  • Pomaylast® approved
  • 2012
  • Kyprolis® approved
  • 2011
  • Record 8 treatments in
    Phase III trials
  • 2011
  • MMRF CoMMpassSM launched
  • 2008
  • Doxil approved
  • 2007
  • Revlimid® approved
  • 2006
  • Thalomid® approved
  • 2004
  • MMRC tissue bank established
  • 2004
  • MMRC founded
  • 2003
  • Velcade® approved
  • 2002
  • Zometa® approved
  • 1998
  • MMRF established

The MMRF changed the multiple myeloma treatment
landscape by removing obstacles and injecting speed at each step of
the research and drug development process.

If you have multiple myeloma,
you have options.

At the MMRF, we’re urgently working to develop treatments to extend your life. We can notify you about clinical trials, connect you to other patients with the same disease characteristics, bring you the latest breaking developments, and more. We’re learning every day. You can too.

LEARN MORE

KNOWLEDGE LEADS TO CURES. Stay informed with our newsletter.

News & Current Events